MoneyWorks4Me

Lincoln Pharmaceuticals Ltd (LINCOLN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531633 NSE: LINCOLN Pharmaceuticals & Drugs | Small Cap | Lincoln Pharma Share Price

₹544.25 -14.25 (-2.55%)

As on 12-Oct'26 16:59

Lincoln Pharmaceuticals Ltd (LINCOLN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531633 NSE: LINCOLN Pharmaceuticals & Drugs | Small Cap | Lincoln Pharma Share Price

₹544.25 -14.25 (-2.55%)

As on 12-Oct'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹1,090 Cr.
Current Price
₹544.3
52-Week Low / High
₹440 / 770
TTM EPS
₹48.2
TTM Sales
₹694 Cr.
Book Value per Share
₹396.3
P/E Ratio
11.30
Lower than its 5-year historical median
Industry PE
52.6
Price to Book (P/B)
1.37
Lower than its 5-year historical median
Price to Sales (P/S)
1.57
Lower than its 5-year historical median
EV/EBITDA
7.39
Lower than its 5-year historical median
Dividend Yield
0.33%
Profitability Efficiency
Return on Equity (ROE)
12.30%
Outperforms industry median
Return on Capital Employed (ROCE)
16.27%
Outperforms industry median
Return on Assets (ROA)
10.11%
Operating Profit Margin
14.8%
Net Profit Margin
13.1%
Gross Profit Margin
18.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
7.67%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-3.75%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
6.73%
Asset Quality
Promoter Holding
49.78%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹774 Cr.
Equity
₹20 Cr.
Face Value
₹10
All Time Low / High
₹8.05 / 975.00

Lincoln Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Fair

Price Trend

Weak
Q.1 Is Lincoln Pharmaceuticals Ltd a good quality company?
Lincoln Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Lincoln Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Lincoln Pharmaceuticals Ltd vs industry peers?
Lincoln Pharmaceuticals Ltd revenue CAGR is 9.61%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Lincoln Pharmaceuticals Ltd?
Promoters hold 49.78% of the Lincoln Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Lincoln Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 9.3% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Lincoln Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ18.6%18.3%21.7%21.8%25.2%24.3%21.8%22.5%17.6%16.3%-
Value Creation
Index ⓘ
0.30.30.60.60.80.70.60.60.30.2-

Growth Parameters ⓘ

Sales ⓘ304325353376423472510581623671694
Sales YoY Gr.-6.8%8.6%6.5%12.5%11.6%8.1%13.8%7.4%7.7%-
Adj EPS ⓘ13.615.121.821.630.733.932.344.537.436.148.2
YoY Gr.-10.8%44.5%-0.9%42.1%10.5%-4.7%37.6%-15.9%-3.7%-
BVPS (₹) ⓘ94.8109.8131.3152.3182.9216.1250.9296335.3378.3396.3
Adj Net
Profit ⓘ
27.230.243.643.261.56864.889.17572.296
Cash Flow from Ops. ⓘ17.821.351.170.769.476.239.263.293106-
Debt/CF from Ops. ⓘ32.60.70.1000.1000-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ9.2%9.7%9.6%7.7%
Adj EPS ⓘ11.4%3.3%3.7%-3.7%
BVPSⓘ16.6%15.6%14.7%12.8%
Share Price 9.1% 7.3% 2.9% 3.7%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ
16.614.818.115.218.31713.916.311.910.112.4
Op. Profit
Mgn % ⓘ
1414.217.115.920.620.317.517.316.314.814.6
Net Profit
Mgn % ⓘ
99.312.411.514.614.412.715.41210.813.9
Debt to
Equity ⓘ
0.30.30.10000000-
Working Cap
Days ⓘ
198221223227227226231224232239110
Cash Conv.
Cycle ⓘ
9394908063647985767081

Valuation of Lincoln Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales360361366386424472510581623671
Operating Expenses ⓘ + 314308299321337377421481522573
Manufacturing Costs35596872697896114136151
Material Costs203156136138156170179204203212
Employee Cost 38515259638093103112125
Other Costs ⓘ 38424352495053607185
Operating Profit ⓘ 4752676687958910010198
Operating Profit Margin (%) 13.0%14.5%18.4%17.0%20.6%20.2%17.5%17.2%16.3%14.6%
Other Income ⓘ + 3561161022342233
Exceptional Items ⓘ 0000000000
Interest ⓘ 7542212121
Depreciation ⓘ 6677889111314
Profit Before Tax ⓘ 374662678496100122109116
Tax ⓘ 9121316212728292728
Profit After Tax 28354951626973938288
PAT Margin (%) 7.8%9.6%13.3%13.3%14.7%14.7%14.3%16.1%13.2%13.1%
Adjusted EPS (₹)14.117.324.425.731.134.636.446.641.143.9
Dividend Payout Ratio (%)8.50%8.70%6.20%5.80%4.80%4.30%4.10%3.90%4.40%4.10%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 192224269313366433502593672758
Share Capital ⓘ 2020202020.0320.0320.0320.0320.0320.03
Reserves ⓘ 172204249293346413482573652738
Debt +5755325022104
Long Term Debt12721000000
Short Term Debt4549304022104
Minority Interest0000000000
Trade Payables32434451577251728585
Others Liabilities ⓘ 41405367644881596569
Total Liabilities ⓘ 324363399437487555637725822916

Fixed Assets

Net Fixed Assets ⓘ +103117121123111132151179182191
Gross Block108128138147142171197237252274
Accumulated Depreciation5111724313947577083
CWIP ⓘ 70202167345
Investments ⓘ 10111834819791139174209
Inventories37453647477370777980
Trade Receivables91109122101113116136162166161
Cash Equivalents 1215815141934142233
Others Assets ⓘ 656691116120102147151194237
Total Assets ⓘ 324363399437487555637725822916
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 252753756976396393106
PBT ⓘ 374662678496100122109116
Adjustment ⓘ 11129951-0-1716
Changes in Working Capital ⓘ -13-22-11402-31-16910
Tax Paid ⓘ -10-9-18-15-19-24-30-26-26-25
Cash Flow From Investing Activity ⓘ + -25-12-18-31-64-78-37-57-79-98
Capex -18-10-15-7-9-45-14-40-19-25
Net Investments -100-6-14-44-23-4-3-30-34
Others ⓘ 2-23-9-11-9-19-15-30-39
Cash Flow From Financing Activity ⓘ + 0-11-36-38-6-3-5-5-60
Net Proceeds from Shares ⓘ 0000000000
Net Proceeds from Borrowing ⓘ -6-7-9-2-1-10000
Interest Paid ⓘ -7-5-4-2-1-1-1-1-2-1
Dividend Paid ⓘ -2-3-4-70-3-3-3-4-4
Others ⓘ 154-18-26-42-0-1-14
Net Cash Flow ⓘ -03-17-1-5-2188
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)17.2916.6319.7517.6718.3217.3515.5917.0413.0212.3
ROCE (%)18.5119.0522.522.324.924.2921.8222.5317.5516.27
Asset Turnover Ratio1.221.050.990.960.950.950.90.890.840.81
PAT to CFO Conversion(x)0.890.771.081.471.111.10.530.681.131.2
Working Capital Days
Receivable Days85.50101112.20102.2089.3084.3086.1089.6091.8085.30
Inventory Days32.4041.7039.5038.2039.1043.9048.7044.3043.6041.30
Payable Days56.5088.50117.60125.80126.80138.40124.60110.30141.70146.30

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

The current trading price of Lincoln Pharma on 12-Oct-2026 16:59 is ₹544.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Oct-2026 the market cap of Lincoln Pharma stood at ₹1,090.1 Cr

The latest P/E ratio of Lincoln Pharma as of 11-Oct-2026 is 11.30.

The latest P/B ratio of Lincoln Pharma as of 11-Oct-2026 is 1.37.

The 52-week high of Lincoln Pharma is ₹770.0 and the 52-week low is ₹439.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lincoln Pharma is ₹694 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lincoln Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Lincoln Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Lincoln Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals was established in 1979 to manufacture and market affordable therapeutic products. Since then, Lincoln Pharmaceuticals has come a long way.

Lincoln Pharmaceuticals is a public limited company with a large shareholder base including members of the medical fraternity. It has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters. There are three different buildings for tablets, capsules and injectables and also a separate building for quality control.

An ultramodern laboratory with state-of-the-art equipments ensures in-house quality assurance of each of the products. The products are designed for all therapeutic segments with a special emphasis on gynecological and orthopedic specialties.

Group of Companies

  • Lincoln Parenterals
  • Karnavati Distributors
  • Down Town Travels
  • Shelavi Paper Mills

Product of the company

  • Tablets 
  • Capsules
  • Injectables
  • Syrups
  • Ointments

Certification

  • WHO-GMP standard
  • ISO 9002 certification 
  • Export House certification
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now